Skip to main content

Advertisement

Log in

Osteoporosis After Transplantation

  • Current Therapeutics (SL Silverman, Section Editor)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Transplantation is an established therapy for end-stage diseases of kidney, lung, liver, and heart among others. Osteoporosis and fragility fractures are serious complications of organ transplantation, particularly in the first post-transplant year. Many factors contribute to the pathogenesis of osteoporosis following organ transplantation. This review addresses the mechanisms of bone loss that occurs both in the early and late post-transplant periods, including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver, cardiac, and bone marrow transplantation. Prevention and treatment for osteoporosis in the transplant recipient are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. Kulak CA, Borba VZ, Kulak Junior J, Campos DJ, Shane E. Post-transplantation osteoporosis. Arq Bras Endocrinol Metabol. 2010;54(2):143–9.

    PubMed  Google Scholar 

  2. Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am. 2007;36(4):937–63. viii.

    Article  PubMed  CAS  Google Scholar 

  3. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res. 1996;11(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  4. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544–50.

    Article  PubMed  CAS  Google Scholar 

  5. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73–81.

    Article  PubMed  CAS  Google Scholar 

  6. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274–82.

    Article  PubMed  CAS  Google Scholar 

  7. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975;40(5):774–9.

    Article  PubMed  CAS  Google Scholar 

  8. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983;32(2):151–6.

    Article  PubMed  CAS  Google Scholar 

  9. Peeters GM, van Schoor NM, van Rossum EF, Visser M, Lips P. The relationship between cortisol, muscle mass and muscle strength in older persons and the role of genetic variations in the glucocorticoid receptor. Clin Endocrinol (Oxf). 2008;69(4):673–82.

    Article  CAS  Google Scholar 

  10. Sun L, Peng Y, Zaidi N, Zhu LL, Iqbal J, Yamoah K, et al. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am J Physiol Renal Physiol. 2007;292(1):F285–91.

    Article  PubMed  CAS  Google Scholar 

  11. Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004;78(8):1233–6.

    Article  PubMed  CAS  Google Scholar 

  12. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant. 1995;9(1):20–4.

    PubMed  CAS  Google Scholar 

  13. Goffin E, Devogelaer JP, Lalaoui A, Depresseux G, De Naeyer P, Squifflet JP, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int. 2002;15(2–3):73–80.

    Article  PubMed  CAS  Google Scholar 

  14. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, de Osaba MJ Martinez, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001;68(2):83–6.

    Article  PubMed  CAS  Google Scholar 

  15. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333(3):166–74.

    Article  PubMed  CAS  Google Scholar 

  16. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–7.

    Article  PubMed  CAS  Google Scholar 

  17. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857–67.

    Article  PubMed  CAS  Google Scholar 

  18. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol. 2000;14(4):342–6.

    Article  PubMed  CAS  Google Scholar 

  19. Kwan JT, Almond MK, Evans K, Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab. 1992;18(2–5):166–8.

    PubMed  CAS  Google Scholar 

  20. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation. 1999;67(9):1218–22.

    Article  PubMed  CAS  Google Scholar 

  21. Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11(7):450–7.

    Article  PubMed  CAS  Google Scholar 

  22. Jastrzebski D, Lutogniewska W, Ochman M, Margas A, Kowalski K, Wyrwol J, et al. Osteoporosis in patients referred for lung transplantation. Eur J Med Res. 2010;15 Suppl 2:68–71.

    PubMed  Google Scholar 

  23. Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, et al. Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int. 2009;20(11):1881–7.

    Article  PubMed  CAS  Google Scholar 

  24. •• Kulak CA BV, Jorgetti, V, Dos Reis LM, Liu XS, Kimmel DB, Kulak J Jr, Rabelo LM, Zhou H, Guo XE, Bilezikian JP, Boguszewski CL, Dempster DW. Skeletal microstructural abnormalities in postmenopausal women with chronic obstructive pulmonary disease. J Bone Miner Res. 2010;9(25):1931–40. In this study it was demonstrated that COPD patients present with microarchitecture deterioration before transplant, and it was related to the amount of smoking.

    Article  Google Scholar 

  25. Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest. 2000;117(2):476–81.

    Article  PubMed  CAS  Google Scholar 

  26. Ferrari SL, Nicod LP, Hamacher J, Spiliopoulos A, Slosman DO, Rochat T, et al. Osteoporosis in patients undergoing lung transplantation. Eur Respir J. 1996;9(11):2378–82.

    Article  PubMed  CAS  Google Scholar 

  27. Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1996;101(3):262–9.

    Article  PubMed  CAS  Google Scholar 

  28. • Stein EM, Cohen A, Freeby M, Rogers H, Kokolus S, Scott V, et al. Severe vitamin D deficiency among heart and liver transplant recipients. Clin Transplant. 2009 Nov-Dec;23(6):861–5. This study demonstrates that vitamin D deficiency is highly prevalent among heart and liver transplant recipients. Ninety-one percent had levels below 75 nmol/L, with the liver recipient patients at greatest risk.

    Article  PubMed  Google Scholar 

  29. •• Dalle Carbonare L, Zanatta M, Braga V, Sella S, Vilei MT, Feltrin G, et al. Densitometric threshold and vertebral fractures in heart transplant patients. Transplantation. 2011 Jul 15;92(1):106–11. This is a cross-sectional study in 180 heart transplant patients showing that standard densitometric criteria were unreliable to identify bone fragility.

    Article  PubMed  Google Scholar 

  30. Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab. 1996;81(5):1740–6.

    Article  PubMed  CAS  Google Scholar 

  31. Sachdeva R, Soora R, Bryant JC, Seibert JJ, Blaszak RT, Frazier EA. Bone mineral status in pediatric heart transplant recipients: a retrospective observational study of an “at risk” cohort. Pediatr Transplant. 2010;14(3):383–7.

    Article  PubMed  Google Scholar 

  32. • McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. 2011;Jan;46(1):1–9. In this paper, the authors recommend screening all adult allogeneic and autologous hematopoietic cell transplantation patients with DXA 1 year after transplantation as well as pediatric patients at risk for bone loss.

    Article  PubMed  CAS  Google Scholar 

  33. Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood. 2004;103(10):3635–43.

    Article  PubMed  CAS  Google Scholar 

  34. Leeuwin RS, Njio KD, Belling GA, van den Hoven S. Glucocorticoid-induced changes in synaptic vesicles of rat phrenic nerve terminals. Arch Int Pharmacodyn Ther. 1983;266(2):200–7.

    PubMed  CAS  Google Scholar 

  35. • Faulhaber GA, Premaor MO, Moser Filho HL, Silla LM, Furlanetto TW. Low bone mineral density is associated with insulin resistance in bone marrow transplant subjects. Bone Marrow Transplant. 2009 Jun;43(12):953–7. This study shows that insulin resistance, low vitamin D, and ferritin levels were associated with low bone mass in bone marrow recipient patients.

    Article  PubMed  CAS  Google Scholar 

  36. Kreutz M, Eissner G, Hahn J, Andreesen R, Drobnik W, Holler E. Variations in 1 alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 serum levels during allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;33(8):871–3.

    Article  PubMed  CAS  Google Scholar 

  37. Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 2003;9(4):321–30.

    Article  PubMed  Google Scholar 

  38. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol. 2002;37(1):93–100.

    Article  PubMed  CAS  Google Scholar 

  39. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, de Osaba MJ Martinez, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001;12(6):484–92.

    Article  PubMed  CAS  Google Scholar 

  40. • Baccaro LF, Boin IF, Pedro AO, Costa-Paiva L, Leal AL, Ramos CD, et al. Decrease in bone mass in women after liver transplantation: associated factors. Transplant Proc. 2011 May;43(4):1351–6. This study shows that estrogen prevents bone loss in premenopausal women after transplantation.

    Article  PubMed  CAS  Google Scholar 

  41. Fabrega E, Orive A, Garcia-Unzueta M, Amado JA, Casafont F, Pons-Romero F. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. Clin Transplant. 2006;20(3):383–8.

    Article  PubMed  Google Scholar 

  42. Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab. 2006;91(2):526–9.

    Article  PubMed  CAS  Google Scholar 

  43. Akeno N, Matsunuma A, Maeda T, Kawane T, Horiuchi N. Regulation of vitamin D-1alpha-hydroxylase and −24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol. 2000;164(3):339–48.

    Article  PubMed  CAS  Google Scholar 

  44. Reichrath J. Dermatologic management, sun avoidance and vitamin D status in organ transplant recipients (OTR). J Photochem Photobiol B. 2010;101(2):150–9.

    Article  PubMed  CAS  Google Scholar 

  45. Briffa NK, Keogh AM, Sambrook PN, Eisman JA. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation. 2003;75(12):2133–4.

    Article  PubMed  CAS  Google Scholar 

  46. El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005;67(5):2039–45.

    Article  PubMed  Google Scholar 

  47. Isoniemi H, Appelberg J, Nilsson CG, Makela P, Risteli J, Hockerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol. 2001;34(2):299–305.

    Article  PubMed  CAS  Google Scholar 

  48. Tierney KD, Facione N, Padilla G, Blume K, Dodd M. Altered sexual health and quality of life in women prior to hematopoietic cell transplantation. Eur J Oncol Nurs. 2007;11(4):298–308.

    Article  PubMed  Google Scholar 

  49. D’Souza AB, Grigg AP, Szer J, Ebeling PR. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J. 2006;36(9):600–3.

    Article  PubMed  Google Scholar 

  50. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14(10):2669–76.

    Article  PubMed  CAS  Google Scholar 

  51. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144(4):239–48.

    PubMed  CAS  Google Scholar 

  52. Giannini S, D’Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001;16(11):2111–7.

    Article  PubMed  CAS  Google Scholar 

  53. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004;350(8):767–76.

    Article  PubMed  CAS  Google Scholar 

  54. Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore CE. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int. 2007;27(3):251–6.

    Article  PubMed  CAS  Google Scholar 

  55. Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int. 2001;12(2):112–6.

    Article  PubMed  CAS  Google Scholar 

  56. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007(3):CD005015.

  57. Malluche HH, Monier-Faugere MC, Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol. 2010;6(1):32–40.

    Article  PubMed  Google Scholar 

  58. Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant. 2008;8(9):1864–70.

    Article  PubMed  CAS  Google Scholar 

  59. •• Stein EM, Ortiz D, Jin Z, McMahon DJ, Shane E. Prevention of Fractures after Solid Organ Transplantation: A Meta-Analysis. J Clin Endocrinol Metab. 2011 Aug 17. This is an important meta-analysis regarding the results from treatment with vitamin D and BPs after transplantation on the reduction of fractures.

  60. Kulak CAM, Shane E: Transplantation Osteoporosis: biochemical Correlates of Pathogenesis and Treatment. In Dynamics of Bone and Cartilage Metabolism, 2nd edition. Edited by Seibel MJ, Robins SP, Bilezikian JP. Philadelphia: Elsevier; 2006:701–716.

Download references

Disclosure

Conflicts of interest: C.A.M Kulak: none; V.Z.C Borba: has received payment for development of educational presentations including service on speakers’ bureaus from Novartis, and has received travel/accommodations expenses covered or reimbursed from Eli Lilly; J. Kulak Jr: none; M.R. Custódio: has received payment for development of educational presentations including service on speakers’ bureaus from Abbott and Amgen.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carolina A. Moreira Kulak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kulak, C.A.M., Borba, V.Z.C., Júnior, J.K. et al. Osteoporosis After Transplantation. Curr Osteoporos Rep 10, 48–55 (2012). https://doi.org/10.1007/s11914-011-0083-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-011-0083-y

Keywords

Navigation